These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 16918260)

  • 1. Role of abciximab in the treatment of coronary artery disease.
    Gabriel HM; Oliveira EI
    Expert Opin Biol Ther; 2006 Sep; 6(9):935-42. PubMed ID: 16918260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
    Lincoff AM; Califf RM; Van de Werf F; Willerson JT; White HD; Armstrong PW; Guetta V; Gibler WB; Hochman JS; Bode C; Vahanian A; Steg PG; Ardissino D; Savonitto S; Bar F; Sadowski Z; Betriu A; Booth JE; Wolski K; Waller M; Topol EJ;
    JAMA; 2002 Nov; 288(17):2130-5. PubMed ID: 12413372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
    Peter K; Kohler B; Straub A; Ruef J; Moser M; Nordt T; Olschewski M; Ohman ME; Kübler W; Bode C
    Circulation; 2000 Sep; 102(13):1490-6. PubMed ID: 11004138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
    Lincoff AM; Califf RM; Topol EJ
    J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Roe MT; Sapp SK; Lincoff AM
    Cleve Clin J Med; 2000 Feb; 67(2):131-40. PubMed ID: 10680279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
    Leclerc JR
    Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
    Peter K; Straub A; Kohler B; Volkmann M; Schwarz M; Kübler W; Bode C
    Am J Cardiol; 1999 Sep; 84(5):519-24. PubMed ID: 10482148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
    Topol EJ; Ferguson JJ; Weisman HF; Tcheng JE; Ellis SG; Kleiman NS; Ivanhoe RJ; Wang AL; Miller DP; Anderson KM; Califf RM
    JAMA; 1997 Aug; 278(6):479-84. PubMed ID: 9256222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction.
    Mak KH; Lee LH; Wong A; Chan C; Koh TH; Lau KW; Lim YL
    Am J Cardiol; 2002 Apr; 89(8):930-6. PubMed ID: 11950430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
    Topol EJ;
    Lancet; 2001 Jun; 357(9272):1905-14. PubMed ID: 11425410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
    Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IIb's are not IIb's.
    Kereiakes DJ; Runyon JP; Broderick TM; Shimshak TM
    Am J Cardiol; 2000 Apr; 85(8A):23C-31C. PubMed ID: 10793177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
    Gurm HS; Lincoff AM; Lee D; Tang WH; Jia G; Booth JE; Califf RM; Ohman EM; Van de Werf F; Armstrong PW; Guetta V; Wilcox R; Topol EJ;
    J Am Coll Cardiol; 2004 Feb; 43(4):542-8. PubMed ID: 14975461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
    Konopka A; Spychalska J; Sitkiewicz D; Zdebska E; Pilichowska I; Piotrowski W; Stepińska J
    Am J Cardiovasc Drugs; 2007; 7(6):433-9. PubMed ID: 18076210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.